Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

Sonnet BioTherapeutics has reported positive safety outcomes from a trial of SON-1010 with atezolizumab for solid tumours or ...

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

The California Institute for Regenerative Medicine (CIRM) has given $8m to biotechnology company Tr1X to support its trial of ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...